Spanish competition authority CNMC has started sanction procedures against the Ireland-based Aspen Group pharmaceutical, as well as its Spanish distributor, Deco Pharma SL, over alleged abuses of market power, including denial of supply of certain drugs, excessive prices, and agreements to limit distribution and cause deliberate shortages.
The actions mentioned would be in violation of the country’s Competition Defense Law, as well as the Treaty on the Function of the European Union, by causing deliberate shortages of certain products in the national market in order to avoid the price guidelines set by the Spanish market, importing said products from other countries and allowing Aspen to set its own prices.
The CNMC’s probe was kick-started after information on these possible uncompetitive practices were notified by the Italian Competition Authority, from where some of the medications involved have been imported.
Full Content: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Pushes Review of CoStar’s Commercial Real Estate Antitrust Case
Jan 31, 2024 by
CPI
UK’s CMA Investigates Ardonagh’s Atlanta Group and Markerstudy Merger
Jan 31, 2024 by
CPI
Greenberg Traurig Grow Financial Regulatory and Compliance Practice
Jan 31, 2024 by
CPI
Dutch Regulator Fines Uber €10 Million for Privacy Violations
Jan 31, 2024 by
CPI
DOJ Investigates AI Competition, Eyes Microsoft’s OpenAI Deal: Bloomberg
Jan 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI